Maxcyte vs Omniab
Maxcyte (MXCT) and Omniab (OABI) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $141M
- Last close
- $1.37
- 12 months
- −15.9%
- Market value
- $680M
- Last close
- $4.66
- 12 months
- +179.0%
At a glance
- The biggest part of Maxcyte's revenue is Product sales (57%); at Omniab it is License and milestone revenue (52%).
- By market value, Omniab ($680M) is about 4.8 times Maxcyte ($141M).
- Over the last 12 months Maxcyte's share price moved −15.9% and Omniab's +179.0%; against the S&P 500 that is −21.7 points and +173.3 points.
- In their last fiscal years Maxcyte kept -135.1% of revenue as net income and Omniab -347.0%.
- In the last 90 days insiders reported 1 open-market purchase at Maxcyte and 0 at Omniab; members of Congress disclosed 0 trades in Maxcyte and 0 in Omniab.
- Next results: Maxcyte Mar 12, 2027, Omniab Mar 2, 2027.
How each one makes money: Maxcyte revenue · Omniab revenue
Share prices on one chart
Maxcyte and Omniab, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Maxcyte MXCTNASDAQ · Services-Commercial Physical & Biological Research | Omniab OABINASDAQ · Services-Commercial Physical & Biological Research | |
|---|---|---|
| Size and profitability | ||
| Market value | $141M | $680M |
| Revenue, last fiscal year | $33M | $18.7M |
| Net income, last fiscal year | −$44.6M | −$64.8M |
| Net marginNet income as a share of revenue | -135.1% | -347.0% |
| Free cash flow | −$36.2M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Common questions
How is Maxcyte different from Omniab?
Maxcyte (MXCT) is in Services-Commercial Physical & Biological Research on NASDAQ, with $33M of revenue in its last fiscal year and a net margin of -135.1%. Omniab (OABI) is in Services-Commercial Physical & Biological Research on NASDAQ, with $18.7M of revenue in its last fiscal year and a net margin of -347.0%. The biggest part of Maxcyte's revenue is Product sales (57%); at Omniab it is License and milestone revenue (52%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Maxcyte and Omniab compare in size?
Omniab has the larger market value: Maxcyte $141M and Omniab $680M, at the last close.
Whose share price rose more over the last 12 months, MXCT or OABI?
Over the last 12 months Maxcyte moved −15.9% and Omniab +179.0%. Past price moves say nothing about the future.
Which has had more insider buying, Maxcyte or Omniab?
Since 2006, Omniab insiders reported 21 open-market purchases against 11 for Maxcyte. These are counts of what was filed, not a view on either stock.
Do members of Congress trade MXCT or OABI?
In the last 12 months, members of Congress disclosed 0 trades in Maxcyte (MXCT) and 0 in Omniab (OABI).
When did insiders last buy MXCT and OABI?
Maxcyte: Nov 18, 2026. Omniab: May 15, 2025.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Maxcyte pageOmniab pageRare insider trades this weekAll comparisons
https://oqro.io/compare/mxct-vs-oabi
